SGLT2 inhibitors do show promise in providing nephroprotection to T1DM patients (Groop et al., 2020) suggesting that even if SGLT2 blockade fails to improve natriuresis, the clinical consequences are not deleterious. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.